EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson’s disease

Jarod Rutledge iD, Benoit Lehallier, Pardis Zarifkar, Patricia Moran Losada, Marian Shahid-Besanti, Dan Western, Priyanka Gorijala, Sephira Ryman, Maya Yutsis, Gayle K Deutsch, Elizabeth Mormino, Alexandra Trelle und 9 weitere

Acta Neuropathologica · 2024-06 · 147 (1)

DOI: 10.1007/s00401-024-02706-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 11.03.2024. Verfasst von Jarod Rutledge und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Stanford University School of Medicine, Stanford University, Stanford, CA, USA. jarod@stanford.edu. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 120-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, Michael J. Fox Foundation for Parkinson's Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease (PD) starts at the molecular and cellular level long before motor symptoms appear, yet there are no early-stage molecular biomarkers for diagnosis, prognosis prediction, or monitoring therapeutic response. This lack of biomarkers greatly impedes patient care and translational research— l -DOPA remains the standard of care more than 50 years after its introduction. Here, we performed a large-scale, multi-tissue, and multi-platform proteomics study to identify new biomarkers for early diagnosis and disease monitoring in PD. We analyzed 4877 cerebrospinal fluid, blood plasma, and urine samples from participants across seven cohorts using three orthogonal proteomics methods: Olink proximity extension assay, SomaScan aptamer precipitation assay, and liquid chromatography–mass spectrometry proteomics. We discovered that hundreds of proteins were upregulated in the CSF, blood, or urine of PD patients, prodromal PD patients with DAT deficit and REM sleep behavior disorder or anosmia, and non-manifesting genetic carriers of LRRK2 and GBA mutations. We nominate multiple novel hits across our analyses as promising markers of early PD, including DOPA decarboxylase (DDC), also known as l -aromatic acid decarboxylase (AADC), sulfatase-modifying factor 1 (SUMF1), dipeptidyl peptidase 2/7 (DPP7), glutamyl aminopeptidase (ENPEP), WAP four-disulfide core domain 2 (WFDC2), and others. DDC, which catalyzes the final step in dopamine synthesis, particularly stands out as a novel hit with a compelling mechanistic link to PD pathogenesis. DDC is consistently upregulated in the CSF and urine of treatment-naïve PD, prodromal PD, and GBA or LRRK2 carrier participants by all three proteomics methods. We show that CSF DDC levels correlate with clinical symptom severity in treatment-naïve PD patients and can be used to accurately diagnose PD and prodromal PD. This suggests that urine and CSF DDC could be a promising diagnostic and prognostic marker with utility in both clinical care and translational research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseHumansDopa DecarboxylaseProteomicsBiomarkersPlasmaOxidoreductases Acting on Sulfur Group DonorsAromatic-L-Amino-Acid Decarboxylases

Substanzen

Dopa DecarboxylaseBiomarkersSUMF1 protein, humanOxidoreductases Acting on Sulfur Group DonorsDDC protein, humanAromatic-L-Amino-Acid Decarboxylases

Autor:innen und Institutionen

  • Department of Genetics, Stanford University School of Medicine, Stanford University, Stanford, CA, USA. jarod@stanford.edu.
  • Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA, USA. jarod@stanford.edu.
  • Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
  • Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.
  • Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Department of Psychiatry, Washington University in St Louis, St Louis, MO, USA.

ORCID-Profile: Jarod Rutledge

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • Michael J. Fox Foundation for Parkinson's Research
  • Alzheimer's Association
  • Knight Initiative for Brain Resilience
  • NIH

Zitieren

APA

Rutledge, J., Lehallier, B., Zarifkar, P., Losada, P. M., Shahid-Besanti, M., Western, D., Gorijala, P., Ryman, S., Yutsis, M., Deutsch, G. K., Mormino, E., Trelle, A., Wagner, A. D., Kerchner, G. A., Tian, L., Cruchaga, C., Henderson, V. W., Montine, T. J., Borghammer, P., …, & Poston, K. L. (2024). Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson’s disease. Acta Neuropathologica, 147(1). https://doi.org/10.1007/s00401-024-02706-0

Vancouver

Rutledge J, Lehallier B, Zarifkar P, Losada PM, Shahid-Besanti M, Western D, et al. Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson’s disease. Acta Neuropathologica. 2024;147(1). doi:10.1007/s00401-024-02706-0

BibTeX
@article{Rutledge2024,
  author = {Rutledge, Jarod and Lehallier, Benoit and Zarifkar, Pardis and Losada, Patricia Moran and Shahid-Besanti, Marian and Western, Dan and Gorijala, Priyanka and Ryman, Sephira and Yutsis, Maya and Deutsch, Gayle K and Mormino, Elizabeth and Trelle, Alexandra and Wagner, Anthony D and Kerchner, Geoffrey A and Tian, Lu and Cruchaga, Carlos and Henderson, Victor W and Montine, Thomas J and Borghammer, Per and Wyss-Coray, Tony and Poston, Kathleen L},
  title = {Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson’s disease},
  journal = {Acta Neuropathologica},
  year = {2024},
  volume = {147},
  number = {1},
  doi = {10.1007/s00401-024-02706-0}
}
Kostenlos starten →